Evidence map›Paper›PMID 33968657›Full record

ArticleTranslational andrology and urology2021

Whole blood

Edmond M Kwan, Heidi Fettke, Megan Crumbaker, Maria M Docanto, Sarah Q To, Patricia Bukczynska, Andrew Mant, Nicole Ng, Siavash Foroughi, Lisa-Jane K Graham and 14 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Edmond M KwanDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Heidi FettkeDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Megan CrumbakerDepartment of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, New South Wales, Australia.
Maria M DocantoDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Sarah Q ToDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Patricia BukczynskaPeter MacCallum Cancer Centre, Melbourne, Australia.
Andrew MantDepartment of Medical Oncology, Eastern Health, Melbourne, Australia.
Nicole NgPeter MacCallum Cancer Centre, Melbourne, Australia.
Siavash ForoughiPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Lisa-Jane K GrahamMedical Oncology, Chris O'Brien Lifehouse, New South Wales, Australia.
Anne-Maree HaynesGarvan Institute of Medical Research, New South Wales, Australia.
Sarah AzerDepartment of Urology, Monash Health, Melbourne, Australia.
Lisi Elizabeth LimDepartment of Medical Oncology, Monash Health, Melbourne, Australia.
Eva SegelovDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Kate MahonGarvan Institute of Medical Research, New South Wales, Australia.
Ian D DavisDepartment of Medical Oncology, Eastern Health, Melbourne, Australia.
Phillip ParenteDepartment of Medical Oncology, Eastern Health, Melbourne, Australia.
Carmel PezaroSheffield Teaching Hospital, Sheffield, UK.
Tilman TodenhöferDepartment of Urology, Eberhard-Karls-University, Tübingen, Germany.
Niranjan SathianathenDivision of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
Christine HauserPeter MacCallum Cancer Centre, Melbourne, Australia.
Lisa G HorvathGarvan Institute of Medical Research, New South Wales, Australia.
Anthony M JoshuaDepartment of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, New South Wales, Australia.
Arun A AzadDepartment of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Monash University · AUEastern Health · AUMonash Health · AUPeter MacCallum Cancer Centre · AUUniversity of Melbourne · AUGarvan Institute of Medical Research · AUSt Vincent's Hospital · AUThe Kinghorn Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood RNA to detect candidate biomarkers in mHSPC remains largely undefined.

methodsIn this cohort study, we used a previously optimised whole blood reverse transcription polymerase chain reaction assay to assess the prognostic utility [measured by seven-month undetectable prostate-specific antigen (PSA) and time to castration-resistance (TTCR)] of eight prostate cancer-associated gene transcripts in 43 mHSPC patients. Transcripts with statistically significant associations (P<0.05) were further investigated in a metastatic castration-resistant prostate cancer (mCRPC) cohort (n=119) receiving contemporary systemic therapy, exploring associations with PSA >50% response (PSA

resultsDetection of circulating Grainyhead-like 2 (

conclusionsDetectable circulating

Indexed as

biomarkercastration-resistantGrainyhead-like 2 (GRHL2)hormone-sensitiveprostate cancer

Identifiers

PMID33968657
PMCPMC8100842
OpenAlexW3140486309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.